93 related articles for article (PubMed ID: 30886125)
1. Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib.
Begg M; Wilson R; Hamblin JN; Montembault M; Green J; Deans A; Amour A; Worsley S; Fantom K; Cui Y; Dear G; Ahmad S; Kielkowska A; Clark J; Boyce M; Cahn A; Hessel EM
J Pharmacol Exp Ther; 2019 Jun; 369(3):337-344. PubMed ID: 30886125
[TBL] [Abstract][Full Text] [Related]
2. Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase
Begg M; Edwards CD; Hamblin JN; Pefani E; Wilson R; Gilbert J; Vitulli G; Mallett D; Morrell J; Hingle MI; Uddin S; Ehtesham F; Marotti M; Harrell A; Newman CF; Fernando D; Clark J; Cahn A; Hessel EM
J Pharmacol Exp Ther; 2019 Jun; 369(3):443-453. PubMed ID: 30940692
[TBL] [Abstract][Full Text] [Related]
3. Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects.
Wilson R; Jarvis E; Montembault M; Hamblin JN; Hessel EM; Cahn A
Clin Ther; 2018 Aug; 40(8):1410-1417. PubMed ID: 30055824
[TBL] [Abstract][Full Text] [Related]
4. An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects.
Harrell AW; Wilson R; Man YL; Riddell K; Jarvis E; Young G; Chambers R; Crossman L; Georgiou A; Pereira A; Kenworthy D; Beaumont C; Marotti M; Wilkes D; Hessel EM; Fahy WA
Drug Metab Dispos; 2019 Dec; 47(12):1457-1468. PubMed ID: 31649125
[TBL] [Abstract][Full Text] [Related]
5. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK2269557 (Nemiralisib) Administered Via Dry Powder Inhaler to Healthy Japanese Subjects.
Ino H; Wilson R; Terao T; Ogura H; Igarashi H; Cahn A; Numachi Y
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):78-86. PubMed ID: 30303626
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals.
Wilson R; Templeton A; Leemereise C; Eames R; Banham-Hall E; Hessel EM; Cahn A
Clin Ther; 2019 Jun; 41(6):1214-1220. PubMed ID: 31076203
[TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.
Cahn A; Hamblin JN; Begg M; Wilson R; Dunsire L; Sriskantharajah S; Montembault M; Leemereise CN; Galinanes-Garcia L; Watz H; Kirsten AM; Fuhr R; Hessel EM
Pulm Pharmacol Ther; 2017 Oct; 46():69-77. PubMed ID: 28823947
[TBL] [Abstract][Full Text] [Related]
9. A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma.
Khindri S; Cahn A; Begg M; Montembault M; Leemereise C; Cui Y; Hogg A; Wajdner H; Yang S; Robertson J; Hamblin JN; Ludwig-Sengpiel A; Kornmann O; Hessel EM
J Pharmacol Exp Ther; 2018 Dec; 367(3):405-413. PubMed ID: 30217958
[TBL] [Abstract][Full Text] [Related]
10. An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome.
Begg M; Amour A; Jarvis E; Tang T; Franco SS; Want A; Beerahee M; Fernando D; Karkera Y; Sander C; Southworth T; Singh D; Clark J; Nejentsev S; Okkenhaug K; Condliffe A; Chandra A; Cahn A; Hall EB
Pulm Pharmacol Ther; 2023 Apr; 79():102201. PubMed ID: 36841351
[TBL] [Abstract][Full Text] [Related]
11. Characterizing Pharmacokinetic-Pharmacodynamic Relationships and Efficacy of PI3K
McLeod RL; Gil MA; Chen D; Cabal A; Katz J; Methot J; Woodhouse JD; Dorosh L; Geda P; Mehta K; Cicmil M; Baltus GA; Bass A; Houshyar H; Caniga M; Yu H; Gervais F; Alves S; Shah S
J Pharmacol Exp Ther; 2019 May; 369(2):223-233. PubMed ID: 30804001
[TBL] [Abstract][Full Text] [Related]
12. Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers.
Moreno O; Butler T; Zann V; Willson A; Leung P; Connor A
Clin Ther; 2018 Nov; 40(11):1855-1867. PubMed ID: 30458930
[TBL] [Abstract][Full Text] [Related]
13. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
14. Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease.
Down K; Amour A; Baldwin IR; Cooper AW; Deakin AM; Felton LM; Guntrip SB; Hardy C; Harrison ZA; Jones KL; Jones P; Keeling SE; Le J; Livia S; Lucas F; Lunniss CJ; Parr NJ; Robinson E; Rowland P; Smith S; Thomas DA; Vitulli G; Washio Y; Hamblin JN
J Med Chem; 2015 Sep; 58(18):7381-99. PubMed ID: 26301626
[TBL] [Abstract][Full Text] [Related]
15. Physiologically Based Pharmacokinetic Modelling of Inhaled Nemiralisib: Mechanistic Components for Pulmonary Absorption, Systemic Distribution, and Oral Absorption.
Miller NA; Graves RH; Edwards CD; Amour A; Taylor E; Robb O; O'Brien B; Patel A; Harrell AW; Hessel EM
Clin Pharmacokinet; 2022 Feb; 61(2):281-293. PubMed ID: 34458976
[TBL] [Abstract][Full Text] [Related]
16. Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials.
Begg M; Hamblin JN; Jarvis E; Bradley G; Mark S; Michalovich D; Lennon M; Wajdner HE; Amour A; Wilson R; Saunders K; Tanaka R; Arai S; Tang T; Van Holsbeke C; De Backer J; Vos W; Titlestad IL; FitzGerald JM; Killian K; Bourbeau J; Poirier C; Maltais F; Cahn A; Hessel EM
Int J Chron Obstruct Pulmon Dis; 2021; 16():1621-1636. PubMed ID: 34113094
[TBL] [Abstract][Full Text] [Related]
17. Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.
Herman AE; Chinn LW; Kotwal SG; Murray ER; Zhao R; Florero M; Lin A; Moein A; Wang R; Bremer M; Kokubu S; Serone AP; Hanze EL; Viberg A; Morimoto AM; Winter HR; Katsumoto TR
Clin Pharmacol Ther; 2018 Jun; 103(6):1020-1028. PubMed ID: 29484638
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Peng B; Hayes M; Resta D; Racine-Poon A; Druker BJ; Talpaz M; Sawyers CL; Rosamilia M; Ford J; Lloyd P; Capdeville R
J Clin Oncol; 2004 Mar; 22(5):935-42. PubMed ID: 14990650
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease.
Sadiq MW; Asimus S; Belvisi MG; Brailsford W; Fransson R; Fuhr R; Hagberg A; Hashemi M; Jellesmark Jensen T; Jonsson J; Keen C; Körnicke T; Kristensson C; Mäenpää J; Necander S; Nemes S; Betts J
Br J Clin Pharmacol; 2022 Jan; 88(1):260-270. PubMed ID: 34182611
[TBL] [Abstract][Full Text] [Related]
20. Levels of IL-32 in Serum, Induced Sputum Supernatant, and Bronchial Lavage Fluid of Patients with Chronic Obstructive Pulmonary Disease.
Gasiuniene E; Lavinskiene S; Sakalauskas R; Sitkauskiene B
COPD; 2016 Oct; 13(5):569-75. PubMed ID: 27018873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
